Enhanced autophagy is required for survival in EGFR-independent EGFR-mutant lung adenocarcinoma cells (Q39111275)

9 September 2017

Enhanced autophagy is required for survival in EGFR-independent EGFR-mutant lung adenocarcinoma cells (English)

1 reference

9 September 2017

0 references

1 reference

Yuji Sakuma

1

1 reference

9 September 2017

Shoichi Matsukuma

2

1 reference

9 September 2017

Yoshiyasu Nakamura

3

1 reference

9 September 2017

Mitsuyo Yoshihara

4

1 reference

9 September 2017

Shiro Koizume

5

1 reference

9 September 2017

Hironobu Sekiguchi

6

1 reference

9 September 2017

Haruhiro Saito

7

1 reference

9 September 2017

Haruhiko Nakayama

8

1 reference

9 September 2017

Yoichi Kameda

9

1 reference

9 September 2017

Tomoyuki Yokose

10

1 reference

9 September 2017

Sachiko Oguni

11

1 reference

9 September 2017

Toshiro Niki

12

1 reference

9 September 2017

Yohei Miyagi

13

1 reference

9 September 2017

12 August 2013

1 reference

9 September 2017

Laboratory Investigation

1 reference

9 September 2017

93

1 reference

9 September 2017

10

1 reference

9 September 2017

1137-1146

1 reference

https://scigraph.springernature.com/pub.10.1038/labinvest.2013.102

9 September 2017

0 references

cites work

Epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.102

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.102

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.102

Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.102

TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.102

Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.102

Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.102

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.102

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.102

Deconvoluting the context-dependent role for autophagy in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.102

Killing a cancer: what are the alternatives?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.102

Association and dissociation of autophagy, apoptosis and necrosis by systematic chemical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.102

Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.102

Pancreatic cancers require autophagy for tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.102

"Autophagic flux" in normal mouse tissues: focus on endogenous LC3A processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.102

A transcriptional variant of the LC3A gene is involved in autophagy and frequently inactivated in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.102

Autophagy is activated in colorectal cancer cells and contributes to the tolerance to nutrient deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.102

Immunohistochemical detection of cytoplasmic LC3 puncta in human cancer specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.102

Combination erlotinib-cisplatin and Atg3-mediated autophagy in erlotinib resistant lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.102

Salinomycin induces autophagy in colon and breast cancer cells with concomitant generation of reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.102

Rapid and simple detection of hot spot point mutations of epidermal growth factor receptor, BRAF, and NRAS in cancers using the loop-hybrid mobility shift assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.102

Simple and precise detection of UGT1A1 polymorphisms with a modified loop-hybrid mobility shift assay using Cy5-labeled loop probes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.102

WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.102

NF-κB signaling is activated and confers resistance to apoptosis in three-dimensionally cultured EGFR-mutant lung adenocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.102

Direct regulation of TWIST by HIF-1alpha promotes metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.102

Hypoxia-inducible factor-1alpha induces Twist expression in tubular epithelial cells subjected to hypoxia, leading to epithelial-to-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.102

Exploiting tumour hypoxia in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.102

Hypoxia, HIF1 and glucose metabolism in the solid tumour

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.102

Hypoxia and serum deprivation-induced apoptosis in mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.102

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.102

Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.102

Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.102

Invasive growth: a MET-driven genetic programme for cancer and stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.102

Targeting MET in cancer: rationale and progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.102

Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.102

Differential detection of KRAS mutations in codons 12 and 13 with a modified loop-hybrid (LH) mobility shift assay using an insert-type LH-generator

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.102

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LABINVEST.2013.102

1 reference

9 September 2017

1 reference